Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03168438 · ClinicalTrials.gov registry record · Phase 1
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03168438 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 6 participants.
The verdict
NCT03168438, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.
Interventions
- DRUG Pembrolizumab
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Letetresgene autoleucel
- DRUG Letetresgene autoleucel with pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-08-18 |
| Est. Completion | 2020-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03168438
The ClinicalTrials.gov registry entry for NCT03168438 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03168438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03168438 about?
NCT03168438 is a clinical study titled "Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma". This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.
What is the current status of trial NCT03168438?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-08-18. Estimated completion is 2020-11-05.
What interventions are being tested in trial NCT03168438?
The interventions under investigation include: Pembrolizumab (DRUG), Cyclophosphamide (DRUG), Fludarabine (DRUG), Letetresgene autoleucel (DRUG), Letetresgene autoleucel with pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03168438?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.